✦ LIBER ✦

383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics

✍ Scribed by C.D. Britten; A.A. Adjei; R. Millham; B. Houk; Z.A. Wainberg; T. Guthrie; G. Dy; P.M. LoRusso

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of PF-04691502, a small-mo

✍ Britten, Carolyn D.; Adjei, Alex A.; Millham, Robert; Houk, Brett E.; Borzillo, 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 286 KB

387 First-in-human study of PF-05212384,

✍ G.I. Shapiro; J. Molina; J. Bendell; I. Braña; J. Spicer; E. Kwak; S. Pandya; R. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Erratum to: Phase I study of PF-04691502

✍ Britten, Carolyn D.; Adjei, Alex A.; Millham, Robert; Houk, Brett E.; Borzillo, 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 67 KB

358 A Multi-arm Phase 1 Dose Escalation

✍ Britten, C.; Wainberg, Z.; Tabernero, J.; Alsina Maqueda, M.; Leong, S.; Sessa, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

334 First-in-human study of the safety,

✍ P.N. Munster; A.W. Tolcher; C.D. Britten; K. Gelmon; S. Moulder; S. Minton; M. M 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB